School of Public Health, Zhejiang University, Hangzhou, People's Republic of China.
Department of Biostatistics, Epidemiology and Environmental Health Sciences, Jiann-Ping Hsu College of Public Health, Georgia Southern University (GSU), Statesboro, USA.
Ethn Health. 2024 Aug;29(6):685-702. doi: 10.1080/13557858.2024.2359387. Epub 2024 Jul 5.
Studies on ovarian cancer (OC) diagnosis, treatment and survival across disaggregated Asian sub-ethnic groups are sparse. Few studies have also conducted trend analyses of these outcomes within and across Asian groups.
Using logistic, Cox, and Joinpoint regression analyses of the 2000-2018 Surveillance, Epidemiology, and End Results (SEER) data, we examined disparities and trends in OC advanced stage diagnosis, receipt of treatments and the 5-year cause-specific survival across seven Asian sub-ethnic groups.
There were 6491 OC patients across seven Asian sub-ethnic groups (mean [SD] age, 57.29 [13.90] years). There were 1583(24.39%) Filipino, 1183(18.23%) Chinese, and 761(11.72%) Asian Indian or Pakistani (AIP) patients. The majority (52.49%) were diagnosed with OC with at an advanced stage. AIP were more likely to have advanced stage diagnosis than other subgroups (ORs, 95%CIs: 0.77, 0.62-0.96 [Filipino]; 0.76, 0.60-0.95 [Chinese]; 0.71, 0.54-0.94 [Japanese]; 0.74, 0.56-0.98 [Vietnamese] and 0.66, 0.53-0.83 [Other Asians]). The Filipinos were least likely to receive surgery but most likely to undergo chemotherapy. Japanese patients had the worst 5-year OC cause-specific survival (50.29%, 95%CI: 46.20%-54.74%). Based on the aggregated analyses, there was a significantly decreased trend in advanced-stage diagnosis and an increased trend in receipt of chemotherapy. Trends in OC outcomes for several subethnicities differed from those observed in aggregated analyses.
In this cohort study of 6491 patients, OC diagnosis, treatment, survival, and trends differed across Asian American ethnic subgroups. Such differences must be considered in future research and interventions to ensure all Asian American subethnicities equally benefit from the advancements in OC care and control.
关于卵巢癌（OC）在亚种族群体中的诊断、治疗和生存的研究很少。很少有研究对这些结果在亚洲群体内部和之间进行趋势分析。
使用 2000 年至 2018 年监测、流行病学和最终结果（SEER）数据的逻辑、Cox 和 Joinpoint 回归分析，我们检查了七个亚洲亚种族群体之间 OC 晚期诊断、治疗和 5 年特定原因生存率的差异和趋势。
在七个亚洲亚种族群体中，有 6491 名 OC 患者（平均[SD]年龄，57.29[13.90]岁）。其中 1583 名（24.39%）为菲律宾人，1183 名（18.23%）为中国人，761 名（11.72%）为亚洲印度或巴基斯坦人（AIP）。大多数（52.49%）患者被诊断为晚期 OC。与其他亚组相比，AIP 更有可能被诊断为晚期 OC（OR，95%CI：0.77，0.62-0.96[菲律宾人]；0.76，0.60-0.95[中国人]；0.71，0.54-0.94[日本人]；0.74，0.56-0.98[越南人]和 0.66，0.53-0.83[其他亚洲人]）。菲律宾人最不可能接受手术，但最有可能接受化疗。日本患者的 OC 特定原因 5 年生存率最差（50.29%，95%CI：46.20%-54.74%）。基于汇总分析，晚期诊断的趋势显著下降，化疗的趋势显著上升。几个亚种族的 OC 结局趋势与汇总分析观察到的趋势不同。
在这项针对 6491 名患者的队列研究中，亚裔美国人亚种族群体之间 OC 的诊断、治疗、生存和趋势存在差异。在未来的研究和干预措施中，必须考虑到这些差异，以确保所有亚裔美国人亚种族群体都能从 OC 护理和控制的进步中平等受益。
